Keryx Biopharmaceuticals, Inc. announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2016. For the quarter, the company’s total revenues for the quarter ended December 31, 2016 are expected to be approximately $9.5 million, compared with $5.8 million during the same period in 2015. Total revenue expectations for the fourth quarter of 2016 consist of approximately $8.2 million in ex-factory Auryxia net U.S. product sales, compared to $4.8 million in the fourth quarter of 2015, which were recorded based on actual prescriptions written during the period. Total expected revenue for the fourth quarter of 2016 also include $1.3 million in license revenues as compared to $1.0 million during the same period in 2015. For the year ended 2016, the company’s total revenues are expected to be approximately $31.9 million as compared to $13.7 million in 2015. Total expected revenues for 2016 include $27.1 million of Auryxia net U.S. product sales and $4.8 million in license revenues as compared to $10.1 million and $3.5 million, respectively in 2015.